These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 31955702)
1. Potential cross-reactivity of polysorbate 80 and cremophor: A case report. Bibera MAT; Lo KMK; Steele A J Oncol Pharm Pract; 2020 Jul; 26(5):1279-1281. PubMed ID: 31955702 [TBL] [Abstract][Full Text] [Related]
2. Possible drug-associated pancreatitis after paclitaxel-cremophor administration. Mills KM; Johnson DM; Middlebrooks M; Burton GV Pharmacotherapy; 2000 Jan; 20(1):95-7. PubMed ID: 10641981 [TBL] [Abstract][Full Text] [Related]
3. Allergy testing for Cremophor in a patient with cervical cancer with infusion reactions to paclitaxel and docetaxel. Nakanishi K; Okazaki S; Ichikawa G; Suzuki S BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35750430 [TBL] [Abstract][Full Text] [Related]
4. A case of severe immediate type reaction to macrogol and polysorbate 60 after intravaginal drug application. Schwede K; Simon JC; Treudler R Eur J Dermatol; 2019 Jun; 29(3):329-331. PubMed ID: 31389792 [No Abstract] [Full Text] [Related]
5. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. Stone CA; Liu Y; Relling MV; Krantz MS; Pratt AL; Abreo A; Hemler JA; Phillips EJ J Allergy Clin Immunol Pract; 2019; 7(5):1533-1540.e8. PubMed ID: 30557713 [TBL] [Abstract][Full Text] [Related]
6. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335 [TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Ley J; Wildes TM; Daly K; Oppelt P; Adkins D Med Oncol; 2017 Feb; 34(2):28. PubMed ID: 28078561 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Colombo T; Parisi I; Zucchetti M; Sessa C; Goldhirsch A; D'Incalci M Ann Oncol; 1999 Apr; 10(4):391-5. PubMed ID: 10370780 [TBL] [Abstract][Full Text] [Related]
9. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. Szebeni J; Muggia FM; Alving CR J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816 [TBL] [Abstract][Full Text] [Related]
11. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Ng SS; Figg WD; Sparreboom A Cancer Res; 2004 Feb; 64(3):821-4. PubMed ID: 14871806 [TBL] [Abstract][Full Text] [Related]
12. Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. Ilinskaya AN; Clogston JD; McNeil SE; Dobrovolskaia MA Nanomedicine; 2015 Nov; 11(8):1925-38. PubMed ID: 26282378 [TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study. Boccia R; Geller RB; Clendeninn N; Ottoboni T Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373 [TBL] [Abstract][Full Text] [Related]
14. Pneumonitis related to treatment with paclitaxel. Goldberg HL; Vannice SB J Clin Oncol; 1995 Feb; 13(2):534-5. PubMed ID: 7844618 [No Abstract] [Full Text] [Related]
15. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. ten Tije AJ; Verweij J; Loos WJ; Sparreboom A Clin Pharmacokinet; 2003; 42(7):665-85. PubMed ID: 12844327 [TBL] [Abstract][Full Text] [Related]
16. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004 [TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157 [TBL] [Abstract][Full Text] [Related]